The Munich-based chemical company WACKER is acquiring 100 percent of the shares in pharmaceutical contract manufacturer Genopis Inc. from Helixmith Co Ltd, Seoul (South Korea) and Medivate Partners LLC, Seoul (South Korea). WACKER will continue Genopis’ existing customer relationships as a contract manufacturer (CDMO) for plasmid DNA (pDNA). The total purchase price for the acquisition consists of a $39 million cash payment due upon closing as well as possible further performance-based payments under a so-called earn-out model. The transaction is expected to close in the 1st quarter of 2021.
Read the full article: WACKER Strengthens Biologics Business by Acquiring US-Based Plasmid DNA Manufacturer Genopis //
Source: https://www.wacker.com/cms/en-us/about-wacker/press-and-media/press/press-releases/detail-152960.html